Healthy
Conditions
Brief summary
The objective of this study is to investigate the safety, tolerability and pharmacokinetics (PK) of VVZ-149 injection after a single dose or loading/maintenance dose in healthy older male volunteers.
Detailed description
VVZ-149 injection, an investigational product (IP) in this clinical study, is a multi-target analgesic drug candidate against glycine transporter type II (GlyT2) and serotonin receptor 2A (5HT2A). The target receptors have been known to play important roles in the induction and transmission of pain signals in the pain-related neural system. There have been efforts to develop new drugs that selectively antagonize the GlyT2 or 5HT2A, but it was unsuccessful due to limitations of single-target drugs. VVZ-149 showed morphine-comparable analgesic and gabapentin-comparable anti-allodynic effects in various rat models of pain.
Interventions
Colorless, transparent liquid in water for injection
OTHERPlacebo
water for injection
Sponsors
Vivozon, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
50 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects who voluntarily agree to participate and sign an IRB-approved informed consent form (ICF) prior to receiving any of the screening procedures 2. Healthy male subjects aged between 50-84, inclusive at screening (the subjects aged 65 years or over can participate only in the single dose trial) 3. Subjects with body weights between 50-90 kg, inclusive and with body mass index (BMI) between 18.0-29.9 kg/m2, inclusive 4. Healthy subjects satisfying eligibility at screening (medical histories, physical examination, vital sign, electrocardiogram (ECG), hematology, clinical chemistry and urinalysis) 5. Subjects who willing to use an medicinal allowed method of contraception or sterility during the study period
Exclusion criteria
1. Subjects who have a presence or history of clinically significant hepatic, renal, neurologic, immunologic, pulmonary, endocrine, hematological, neoplastic, cardiovascular or psychiatric (e.g. mood disorders or obsessive-compulsive disorder) diseases (subjects with currently well-controlled conditions including hypertension, hyperlipidemia, arthritis, prostatic hypertrophy and cataracts may allow to participate at the discretion of the investigator.) 2. Subjects with chronic infection or meaningful acute infection 3. Subjects who have a history of clinically significant hypersensitivities or hypersensitivities to the ingredient of same family with IP and other drug (e.g. aspirin and antibiotics) 4. Subjects who have a family history of chronic pain or with a first-degree relative with chronic pain 5. Subjects who have a clinically significant ECG abnormalities or QTc interval \>450 ms 6. Subjects who meet the following criteria at screening: * AST or ALT level \> 3 times the upper limit of the normal range * Calculated eGFR by MDRD equation \< 60 ml/min * Platelets ≤ 75,000/mm3, Hemoglobin ≤ 9 g/dL, Neutrophils absolute ≤ 1000/mm3 7. Subjects who show the following vital signs at the screening: * Systolic Blood Pressure (SBP): \<92 mmHg or \>160 mmHg * Diastolic Blood Pressure (DBP): \<50 mmHg or \>95 mmHg 8. Subjects who have a history of drug abuse or a positive urine screening for drug abuse 9. Subjects who have taken any prescribed or herbal medicine within one week before the first administration of the IP or any non-prescribed medicine or vitamin supplement within three days before the first administration of the IP (if all other conditions are satisfied, these subjects may be eligible for the trial as judged by the investigator) 10. Subjects who have participated in any other clinical trial within two months before the first administration of the IP 11. Subjects who have donated a unit of whole blood within two months or blood components within one month before the first administration of the IP, or who have received blood transfusion within one month before the first administration of the IP 12. Subjects who consume more than 21 units of alcohol per week (1 unit = 10 g of pure alcohol) or who are unable to abstain from drinking throughout the trial 13. Smokers who consume more than average of 10 cigarettes per day over the past three months or who are unable to abstain from smoking throughout the trial 14. Subjects who consume or are unable to abstain from products containing caffeine (e.g. coffee, green tea, black tea and sodas) within 24 hours before the first administration of the IP and until discharge from the hospital 15. Subjects judged ineligible for the study by the investigator for reasons of medical, psychological, social and geographical conditions causing poor study compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity and maximum tolerated dose | 8 day | Any Common Toxicity Criteria for Adverse Effects grade 3 or more adverse event , All significant toxicity judged by the investigator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability as measured by Adverse event, physical examination, vital signs, 12-lead ECG, consecutive ECG, SpO2 monitoring and Clinical laboratory. | 8 day | Adverse event, physical examination, vital signs, 12-lead ECG, consecutive ECG, SpO2 monitoring, Clinical laboratory |
Other
| Measure | Time frame | Description |
|---|---|---|
| The pharmacokinetics parameters: AUClast, AUCinf and Cmax | [Single Dose Trial] * Blood sampling (17 times) pre-dose and 0.25, 0.5, 1, 2, 3, 4, 4.25, 4.5, 5, 5.5, 6, 7, 8, 12, 24 and 32 h post-dose * Urine collection (5 times) pre-dose and 0-6, 6-12, 12-24 and 24-32 h post-dose [Loading/maintenance Dose Trial] * | Blood sampling and urine sampling |
Outcome results
None listed